ESC Premium Access

Current controversies in antithrombotic therapy

Event: ESC Asia with APSC & AFC 2021
Topic: Pharmacology and Pharmacotherapy
Session type: Debate Session
Date: 3 December 2021
Time: 03:40 - 04:25

Session

Become an ESC member to access this resource

Become a member

Already a member? Sign in

4 presentations in this session

Aspirin in primary prevention: is it still valid?

Speaker: Professor J. Armitage (Oxford, GB)
Thumbnail

Which antithrombotic therapy after transcatheter aortic valve procedure (TAVI)?

Speaker: Professor S. Windecker (Bern, CH)
Thumbnail

Which antithrombotic therapy after percutaneous coronary intervention (PCI)?

Speaker: Professor K. Park (Seoul, KR)
Thumbnail

Current controversies in antithrombotic therapy - panel discussion.

Thumbnail

3 speakers from this session

Professor Jane Armitage

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)
10 presentations
1 follower

Professor Stephan Windecker

Bern University Hospital, Inselspital, Bern (Switzerland)
29 presentations
4 followers

Professor Kyung Woo Park

, Seoul (Korea (Republic of))
4 presentations
0 follower

Related content

ESC Premium Access

Update on endocarditis in 2021

3 December 2021

ESC Premium Access

Pregnancy in women with cardiovascular disease

3 December 2021

ESC Premium Access

Opening session

2 December 2021

This platform is supported by

logo Novo Nordisk